First generic equivalent to Tamiflu debuts in the USA

12 December 2016

The first generic equivalent to Swiss pharma giant Roche’s (ROG: SIX) influenza drug Tamiflu (oseltamivir phosphate) capsules has been launched in the USA.

Privately-held US pharma Alvogen and its partner Indian generics firm Natco Pharma (BSE: 524816) gained US Food and Drug Administration approval for their generic equivalent to Tamiflu in August this year, and Alvogen says it expects to deliver significant savings for patients and health providers of up to $500 million during this upcoming flu season. The product is available in three strengths (30mg, 45mg and 75mg).

As a result of a mild flu season last year, global Tamiflu sales slid 28% to $ 715 million. US sales of Tamiflu were around $403 million for 12 months ending December 2015, according to IMS Health data previously quoted by Natco.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK